ArticleCancers2023

Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis.

Melissa M De Meza et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.